A carregar...

Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents

The optimal dose for treating patients with a molecularly targeted agent may differ according to the patient’s individual characteristics, such as biomarker status. In this article, we propose a Bayesian phase I/II dose-finding design to find the optimal dose that is personalized for each patient ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Stat Assoc
Main Authors: Guo, Beibei, Yuan, Ying
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7451208/
https://ncbi.nlm.nih.gov/pubmed/32863478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/01621459.2016.1228534
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!